Mainz Biomed N.V (MYNZ) Common Equity: 2020-2024
- Mainz Biomed N.V's Common Equity rose 86.09% to $6.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.0 million, marking a year-over-year increase of 86.09%. This contributed to the annual value of $6.0 million for FY2024, which is 86.09% up from last year.
- According to the latest figures from Q4 2024, Mainz Biomed N.V's Common Equity is $6.0 million, which was up 246.10% from -$4.1 million recorded in Q2 2024.
- Mainz Biomed N.V's 5-year Common Equity high stood at $14.1 million for Q4 2022, and its period low was -$4.1 million during Q2 2024.
- Over the past 3 years, Mainz Biomed N.V's median Common Equity value was $4.6 million (recorded in 2023), while the average stood at $4.8 million.
- In the last 5 years, Mainz Biomed N.V's Common Equity spiked by 332.03% in 2021 and then tumbled by 76.95% in 2023.
- Mainz Biomed N.V's Common Equity (Quarterly) stood at -$2.7 million in 2020, then skyrocketed by 332.03% to $6.4 million in 2021, then spiked by 121.60% to $14.1 million in 2022, then slumped by 76.95% to $3.2 million in 2023, then soared by 86.09% to $6.0 million in 2024.
- Its Common Equity stands at $6.0 million for Q4 2024, versus -$4.1 million for Q2 2024 and $3.2 million for Q4 2023.
